Certain Amarin debt holders get a sweetener

Through its wholly-owned subsidiary Corsicanto Limited, certain holders of Amarin's (AMRN -8.6%) outstanding 3.50% Exchangeable Senior Notes issued on January 9, 2012 valued at $118.7M exchange their holdings for new Exchangeable Senior Notes with a lower conversion price. The original notes' conversions were 113.4752 ADSs/$1000 in principal amount. Amarin's price/ADS was, of course, much higher at the time. The new debt will have a conversion option of 384.6154 ADSs/$1000 in principal amount.

The conversion rates in the old and new notes are based on ADS prices of $8.81 and $2.60, respectively.

From other sites
Comments (1)
  • ralphey
    , contributor
    Comments (382) | Send Message
    Studies are pouring in revealing EPA's advantages at the cellular level - DHA now viewed as contaminant


    newest studies reveal that EPA is acting like statins on inflammatory responses within arterial wall.


    AMRN KOWA realize that the combo of EPA / statin will be superior to statin alone and will eventually capture large portion of statin market - ie statin epa combo will be superior to statin alone
    15 May 2014, 01:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs